Mount Sinai Begins Pilot of Respiratory Disease Management Platform
The Department of Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai is conducting an investigational pilot study of a respiratory disease management platform, developed by Cohero Health, in pediatric asthma patients seen in two high volume pediatric clinics at the Mount Sinai Health System. Patients will use Cohero’s platform that employs connected devices and a game-based mobile app to increase and monitor adherence to asthma medication.
“Mount Sinai's work with CoheroHealth demonstrates its commitment to clinical innovation through technology and entrepreneurship,” said Daniel Seltzer, Director of the Center for Technology Innovation and Entrepreneurship (C-TIE) at Mount Sinai Health System; the Cohero Health team worked closely with C-TIE in developing its innovative platform and helping bring it to market.
Cohero’s platform consists of their HeroTracker™ sensor that attaches to a medication inhaler to track medication use and syncs wirelessly to Cohero’s AsthmaHero™ mobile application. The app tracks adherence over time, generates customized reminders and provides a game experience that offers patients in-app and monetary rewards for consistently taking their medication as prescribed. It can also provide parents and caregivers with real time updates of patient medication use as well as weekly and monthly summary reports. The system also incorporates a mobile spirometer to track clinically relevant lung function measures between office visits.
“Cohero is a result of my years of research in chronic respiratory care,” said Cohero co-founder Melissa Manice, PhD, a Post-Doctoral Fellow in the Department of Population Health Science and Policy at Mount Sinai. “Our platform was designed to address the hurdles to proper care and help reduce the overall cost of treating respiratory disease.”
"Adherence to controller medication is essential for the proper treatment of asthma. I’m looking forward to seeing how Cohero's technology of reminding and rewarding patients will improve adherence,” said Dr. Andrew Ting, Pediatric Pulmonologist at The Mount Sinai Hospital.
In addition, by collecting data on controller and rescue medication use, along with the resulting changes in pulmonary function, Cohero is able to conduct predictive analytics in novel ways. “At the patient-level, the platform enables identification of exacerbations and their causes before they occur. On a macro-level, it enables analysis of how patient populations use respiratory drugs, and the resulting effect on lung function,” said Cohero co-founder Daniel Weinstein.
Cohero’s technology supports EMR integration, which enables patient data to be transferred automatically and securely directly into a patient’s record. "Having ready access to adherence and spirometry data will give me a much clearer picture of what's happening with my patients, and will be helpful for our clinical decision making," said Dr. Ting.
The study will measure improvements in medication adherence and lung function of patients using Cohero’s platform as compared to a control group.
About CoheroHealth, LLC
CoheroHealth is a digital health company focused on bringing innovative technologies to improve respiratory care. The company uses connected devices and an interactive, game based, mobile application to track and improve medication adherence and lung function. The company is located in New York City, and is a participant in StartupHealth, Springboard, and GrandCentral Tech startup accelerator programs. Dr. Melissa Manice is a co-founder and equity-holder in CoheroHealth. Visit http://www.coherohealth.com or email firstname.lastname@example.org for more information.
About the Mount Sinai Health System
The Mount Sinai Health System is New York City's largest integrated delivery system encompassing seven hospital campuses, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai's vision is to produce the safest care, the highest quality, the highest satisfaction, the best access and the best value of any health system in the nation.
The System includes approximately 6,600 primary and specialty care physicians; 10 joint-venture ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. The Icahn School of Medicine is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report's "Best Medical Schools", aligned with a U.S. News & World Report's "Honor Roll" Hospital, No. 13 in the nation for National Institutes of Health funding, and among the top 10 most innovative research institutions as ranked by the journal Nature in its Nature Innovation Index. This reflects a special level of excellence in education, clinical practice, and research. The Mount Sinai Hospital is ranked No. 18 on U.S. News & World Report's "Honor Roll" of top U.S. hospitals; it is one of the nation's top 20 hospitals in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Geriatrics, Nephrology, and Neurology/Neurosurgery, and in the top 50 in four other specialties in the 2017-2018 "Best Hospitals" issue. Mount Sinai's Kravis Children's Hospital also is ranked nationally in five out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 12th nationally for Ophthalmology and 50th for Ear, Nose, and Throat, while Mount Sinai Beth Israel, Mount Sinai St. Luke's and Mount Sinai West are ranked regionally.